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Abstract 
Differentiated thyroid carcinoma (DTC) results from complex interactions between genetic and 
environmental factors. Known etiological factors include exposure to ionizing radiations, previous thyroid 
diseases, and hormone factors. It has been speculated that dietary acrylamide (AA) formed in diverse foods 
following the Maillard’s reaction could be a contributing factor for DTC in humans. Upon absorption, AA is 
biotransformed mainly by cytochrome P450 2E1 (CYP2E1) to glycidamide (GA). Considering that 
polymorphisms within CYP2E1 were found associated with endogenous levels of AA-Valine and GA-Valine 
hemoglobin adducts in humans, we raised the hypothesis that specific CYP2E1 genotypes could be 
associated with the risk of DTC. Analysis of four haplotype tagging SNPs (ht-SNPs) within the locus in a 
discovery case–control study (N = 350/350) indicated an association between rs2480258 and DTC risk. This 
ht-SNP resides within a linkage disequilibrium block spanning intron VIII and the 3′-untranslated region. 
Extended analysis in a large replication set (2429 controls and 767 cases) confirmed the association, with 
odds ratios for GA and AA genotypes of 1.24 (95 % confidence interval (CI) 1.03–1.48) and 1.56 (95 % CI, 
1.06–2.30), respectively. Functionally, the minor allele was associated with low levels of CYP2E1 mRNA and 
protein expression as well as lower enzymatic activity in a series of 149 human liver samples. Our data 
support the hypothesis that inter-individual differences in CYP2E1 activity could modulate the risk of 
developing DTC suggesting that the exposure to specific xenobiotics, such as AA, could play a role in this 
process. 
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 Introduction 
Thyroid cancer constitutes approximately 1 % of all human cancer and is the most common endocrine 
malignancy (Sipos and Mazzaferri 2010). The papillary (PTC) and the follicular thyroid carcinoma (FTC), 
overall defined as differentiated thyroid carcinoma (DTC), cover about 95 % of all types of thyroid 
neoplasms (Grande et al. 2012). The main etiological factors responsible for DTC are inheritance 
(Malchoff and Malchoff 2004), exposure to ionizing radiations (Ron 2007), insufficient iodine intake 
(Cardis et al. 2005), previous thyroid diseases such as goiter, and hormonal factors (Surks et al. 1990). 
Fioretti and collaborators showed that a history of benign thyroid disease accounted for 18.9 % of cases, 
radiotherapy for 1.2 %, residence for ≥20 years in endemic goiter areas for 2.4 % of cases, and their 
combination for 21.7 % of thyroid cancer cases; selected indicators of a poor diet accounted for 40.9 % of 
thyroid cancer cases in this population (Fioretti et al. 1999). The combination of all factors considered 
explained over 57 % of thyroid cancer cases in both sexes. However, other environmental factors are 
suspected to play a role, because an increasing incidence is observed in recent years. A possible role of 
acrylamide (AA) for thyroid carcinogenesis has been debated since the first observations in animals 
(Johnson et al. 1986). Acute in vivo treatments of rats with AA resulted in morphological changes of 
thyroid follicular cells, thyroid stimulation, increased levels of serum T4, decreased TSH levels (Khan et 
al. 1999), increased rates of DTC in carcinogenicity assays (Friedman et al. 1995; Beland et al. 2013), and 
even increased rates of FTC (Maronpot et al. 2015). 
Humans are exposed to AA through their diet. The formation of AA in food occurs via the Maillard’s 
reaction between amino acids and sugars at high temperatures during browning and frying (Tareke et 
al. 2002; Mottram et al. 2002; Stadler et al. 2002; Yaylayan et al. 2003; Zyzak et al. 2003). The exposure 
of humans to AA should not be underestimated, representing a real concern for public health (Mottram 
et al. 2002; Stadler et al. 2002; Mei et al. 2008). In fact, potato chips and French fries contain elevated 
concentrations of AA (240 μg/kg). However, significant exposure to AA comes also from bread (9–
24 μg/kg), coffee (200–520 μg/kg), and other foods, including cooked meat (82–84 μg/kg) (EFSA 2012; 
Friedman 2003; Freisling et al. 2013), resulting in an average intake of 0.31–1.1 µg/kg body weight per 
day (EFSA 2011; Pedreschi et al. 2014). A positive association between AA dietary intake and risk of 
endometrial (Hogervorst et al. 2007; Obón-Santacana et al. 2014), ovarian (Hogervorst et al. 2013), and 
renal cancers (Pelucchi et al. 2011) was found in humans. An increased risk was also reported for DTC in a 
French study (Colonna et al. 2010). After a revision of published studies, the International Agency for 
Research on Cancer (IARC) classified AA as a probable human carcinogen (group 2A) (Iarc 1994). 
It was shown that upon absorption, AA is metabolically activated mainly by CYP2E1 to glycidamide (GA) 
(Sumner et al. 1999; Ghanayem et al. 2005; Settels et al. 2008). In humans, it was shown that inhibition 
of CYP2E1 profoundly affects the hematologic and urinary GA/AA ratio in in vivo experiments 
(Doroshyenko et al. 2009). CYP2E1 is a polymorphic enzyme and CYP2E1 gene variants are related to the 
activity of the encoded enzyme, although systematic investigations are missing (Neafsey et al.  2009; 
Zanger and Schwab 2013; http://www.cypalleles.ki.se/). Moreover, in a recent work, Huang et al. (2012) 
found that genotypes of CYP2E1 contribute to the inter-individual variability in endogenous levels of AA-
Valine and GA-Valine hemoglobin adducts (Huang et al. 2012). 
Following all these considerations, we hypothesized that exposure to AA could increase the risk of 
developing DTC and that CYP2E1 polymorphisms may modulate this risk by metabolic interference. For 
this reason, in the present work, we performed a case–control association study on DTC by genotyping 
haplotype tagging single nucleotide polymorphisms (ht-SNPs) within CYP2E1. Corroborating our 
hypothesis, we found a statistically significant association between a SNP tagging the linkage 
disequilibrium (LD) block at the 3′ end of the gene and risk of DTC. Moreover, using human liver tissues 
we showed that variants in this genetic region affect the expression and function of the enzyme. Our 
findings extend the current knowledge about CYP2E1 functional polymorphisms, in particular within the 
3′ region, and their potential involvement in cancer risk. 
Materials and methods 
Case–control study 
DTC patients were volunteers followed up at the Department of Endocrinology of the University Hospital 
of Pisa (Italy). Details of the ongoing study were already given elsewhere (Cancemi et al.  2011). Briefly, 
controls were blood donors collected at Meyer Hospital of Florence (Italy) and healthy subjects working 
at the University Hospital of Pisa recruited during their routine visits in the context of a program of 
surveillance performed by the Occupational Medicine. The eligibility criteria were the same for cases and 
controls, and it included a minimal age of 18 years. As exclusion criteria, volunteers should not have been 
affected by any malignancy, chronic inflammatory disease, or related diseases in the past. A further 
exclusion criterion for controls was the presence of thyroid nodules, when known. The interview of both 
cases and controls was carried out via self-administered questionnaires during blood withdrawal. For 
each subject, the following data were collected: ethnicity, gender, age, height, body weight, birthplace 
and years of residence in the birthplace, place of residence, smoking habits, smoking history, and any 
positive family history of thyroid disease. In the present study, 1140 consecutive cases and 2800 controls 
were analyzed in two independent sample sets. The first (the “discovery set,” DS) consisted of 350 cases 
and 350 controls, while the remaining set of volunteers were included as “replication set” (RS). 
Peripheral blood samples, otherwise disposed following the analyses of clinical routine, were used for 
genetic analyses. The study was approved by the ethics committee of the University of Pisa and 
conducted in accordance with the Helsinki Declaration. All volunteers gave written informed consent to 
participate in the study and to allow the use of their biological samples for research purposes. 
SNP selection 
CYP2E1 is localized on chromosome 10 from 133,527 kb to 133,539 kb (Build GRCh38: December 2013, 
hg38). Three blocks of LD were identified in Caucasians with the tool Haploview (Barrett et al.  2005) and 
the method of confidence intervals (Gabriel et al. 2002). Four ht-SNPs were chosen with MAF (minor 
allele frequency) >10 % using the tagger function (SNP ID in the dbSNP 
at http://www.ncbi.nlm.nih.gov/snp/ and HGVS, the Human Genome Variation Society, names are given 
below): rs9418982 (NC_000010.10:g.133507118C>T) belongs to the first block of LD, within the promoter 
region (133,507,118–133,527,063 bp), and it is in high LD with the polymorphisms PstI and RsaI, 
repeatedly studied in previous works and known as *5A and *5B alleles; rs7092584 
(NC_000010.10:g.133,534,753 C>T) and rs743534 (NC_000010.10:g. 133,535,722 C>A) are located in the 
second block (133,531,207–133,535,722 bp); rs2480258 (NC_000010.10:g. 133,538,596 T>C) is located in 
the third block (133,535,863–133,546,944 bp). 
DNA extraction and SNP genotyping 
DNA extraction was performed on peripheral blood using the PureGene Blood Kit (Gentra Systems, Inc., 
Minneapolis, MN). Samples from cases and controls were randomized and mixed on PCR plates, so that 
an equal number of cases and controls could be analyzed simultaneously by personnel blinded for the 
case/control status. Genotyping for rs9418982, rs7092584, rs743534, and rs2480258 was carried out 
using pre-designed TaqMan® SNP Genotyping Assays, according to protocol specified by the 
manufacturer (Life Technologies Inc., Grand Island, New York, USA). Four percent of DNA samples were 
repeated as quality control. 
Genotypes of rs9418982, rs7092584, rs743534, and rs2480258 were in agreement with Hardy–Weinberg 
equilibrium. The quality control of genotypes was satisfactory (repetitions gave >99.5 % of identities). 
Human liver samples 
Liver tissues and corresponding blood samples for genomic DNA extraction were previously collected 
from Caucasian patients undergoing liver surgery at the Department of General, Visceral, and 
Transplantation Surgery at the Charité (Campus Virchow, University Medical Center Charité, Humboldt 
University Berlin, Germany). The use of human liver tissues was approved by the local ethical committees 
the Charité, Humboldt University (Berlin, Germany), and the University Clinic Tuebingen, Germany. 
Written informed consent was obtained from all liver donors, and the study was conducted in 
accordance with the Declaration of Helsinki. All tissue samples had been examined by a pathologist, and 
only histologically normal liver tissue was collected and stored at −80  °C. For this study, we used 149 liver 
samples for which the following information was available (Klein et al. 2010): gender [male (n = 71) vs. 
female (n = 78)], age [median age = 59 years], smoking habits [smokers (n = 29) vs. non-smokers 
(n = 116)], alcohol consumption [yes (n = 48) vs. no (n = 95)], presurgical drug exposure [yes (n = 109) vs. 
no (n = 40)], cholestasis [yes (n = 25) vs. no (n = 120)], CRP [elevated levels (n = 7) vs. normal levels 
(n = 139)] and the diagnosis leading to liver resection [primary liver tumors (n = 66) vs. metastases 
(n = 82)]). Sample numbers do not always sum up to 149 because of missing information. The genotypes 
for the SNP rs2515642 were extracted from SNP microarray analysis (Schröder et al. 2013). We used the 
SNP microarray data to impute the genotypes of rs2480258 based on the CEU HapMap3 and 1000G 
reference panel (release June 2010, b36) using SHAPEIT v2 and IMPUTE v2.3.1 pipeline (Howie et 
al. 2009, Delaneau et al. 2012). Prior to imputation, low-quality variants (MAF <1 %, call rate <95 % and 
HWE Pvalue <10−6) were filtered out. The software was run using default options, and for each liver 
sample the corresponding genotype for rs2480258 was assigned to the highest maximum posterior 
probability output except that for a value <0.4 a missing genotype was assigned instead. For the SNP 
rs2480258 average certainty of best-guess genotype and info score, which were referred to as 
imputation quality scores, was 0.99 for both metrics. 
Hepatic CYP2E1 expression phenotypes 
High-quality total RNA was isolated from liver tissue using Trizol® (Invitrogen, CA, USA)/Qiagen 
RNeasy® protocol as described previously (Gomes et al. 2009). Expression of CYP2E1 mRNA was 
quantified using pre-developed TaqMan Gene Expression Assay and a TaqMan 7500 system (Applied 
Biosystems, Darmstadt, Germany) as described (Rieger et al. 2013). CYP2E1 protein expression was 
analyzed by Western blot in liver microsomes (Tremmel et al. 2015). CYP2E1 enzyme activity was 
quantified by measuring liver microsomal chlorzoxazone 6-hydroxylation by LC-MSMS analysis as 
described (Gomes et al. 2009). 
In silico analyses 
For the analysis of LD in cases and controls, HapMap project (Data release 28, PhaseII + III, August 10, on 
NCBI B36 assembly, dbSNP b126; http://www.hapmap.org) was browsed. For intronic SNPs, the effect on 
splicing was evaluated with two online prediction tools. The first, “Splice Site Prediction by Neural 
Network,” is a software developed within Berkeley Drosophila Genome Project (freely available at the 
URL: http://www.fruitfly.org/seq_tools/splice.html; Reese et al. 1997), whereas “SpliceAid” is a database 
of strictly experimentally assessed target RNA sequences in humans (available at the 
URL: http://www.introni.it/splicing.html; Piva et al. 2009). Moreover, in order to estimate the effect of 
SNPs falling within miRNA binding sites (the so-called miRSNPs) of mRNAs, the tools PolymiRTS Database 
3.0 (available at the URL http:/compbio.uthsc.edu/miRSNP; Ziebarth et al. 2012; Bhattacharya et 
al. 2014), RNAhybrid (available at the URL: http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/; 
Rehmsmeier et al. 2004), and MicroSnipers (available at the URL:http://epicenter.ie-
freiburg.mpg.de/services/microsniper/) were used with modalities employed in previous studies 
(Naccarati et al. 2012). 
Statistical analyses 
Hardy–Weinberg equilibrium in controls was tested for each polymorphism by the Chi-squared test (χ2) 
test (1 degree of freedom). A logistic regression analysis was used to examine the associations between 
the genotypes and the considered risk factors. The association analyses were based on the estimation of 
the odds ratios (ORs) and of their 95 % confidence intervals (CIs). Genotypes were analyzed with a 
multivariate logistic regression (MLR) model, allowing the ORs to be adjusted for covariates  as linear 
variables (the ORadj). Each genotype category was compared using the common homozygotes as 
reference category, and the P value of the association (P ass) was calculated separately for heterozygotes 
and homozygotes. In the additive model the SNP was coded as the number of risk alleles: 
0 = homozygous reference, 1 = heterozygous, 2 = homozygous variant, and the MLR was performed 
providing the per-allele risk. Moreover, the MLR analysis was performed on the dominant or recessive 
models according to the most likely mode of inheritance, evaluated with an extended MAX test (Freidlin 
et al. 2002). Finally, the total number of alleles was analyzed by counting the total number of risk and 
reference alleles among cases and controls in a 2 × 2 table. The correction of probabilities for multiple 
testing was performed according to the calculation of the false discovery rate following the Benjamini 
and Hochberg procedure (Benjamini et al. 2001). The software Statgraphics Centurion software 
(StatPoint Inc., USA) was used. 
Statistical analysis of the liver samples was performed using the software R 3.0.1 (R Core Team 2014) 
with the additional package SNPassoc-1.9-2 (González et al. 2007). The influence of the polymorphisms 
on CYP2E1 mRNA, protein, and activity phenotypes was investigated using pairwise t tests. Multivariate 
association analysis between the SNP rs2480258 under three different genetic models (additive, 
dominant, and recessive) and each CYP2E1 phenotype measurement, corrected for the eight non-genetic 
factors, was performed using the generalized linear model function of the SNPassoc package. For all 
analyses CYP2E1 phenotype measurements were power-transformed (mRNA: λ = 0.45; protein: λ = 0.3) 
or log-transformed (CYP2E1 enzyme activity) to fulfill Gaussian distribution assumption which was 
confirmed using normal quantile–quantile plots and Shapiro–Wilk tests (all P values >0.57). The 
transformed phenotypes showed homogeneity of variances which was verified using Levene’s tests 
(all P values >0.4). The statistical threshold of significance was 5 %. All statistical tests were two-sided. 
Results 
General patient’s characteristics and discovery set analysis 
The characteristics of the populations employed in the DS and in the RS are reported in Table 1. Females 
were more frequent among cases than controls (OR = 3.28, 95 % CI = 2.39–4.50; OR = 2.97, 95 % 
CI = 2.55–3.46, in DS and RS, respectively), with a sex ratio typical of the disease. Moreover, it should be 
also noted that cases had a slightly lower age than controls. Finally, a positive association was also 
observed between smoking habit and risk of DTC with an OR of 1.37 (95 % CI = 1.18–1.57) in the RS. 
 
The ORadj, the 95 % CIs, and their P ass following MLR analysis of the additive and the best inheritance 
models are reported in Table 2 for the DS. After analysis of 350 cases and 350 controls, no association 
was observed between rs9418982, rs7092584, rs743534, and risk of DTC. On the other hand, uncommon 
homozygotes for rs2480258 showed a statistically significantly increased risk (OR = 2.63, 95 % CI = 1.15–
6.03; P ass = 0.02). The Cochran–Armitage trend test suggested the recessive model as the best genetic 
model of inheritance (Ptrend = 0.02). Under this model, the AA-genotype was related to an increased 
predisposition to DTC (OR = 2.57, 95 % CI = 1.14–5.83; P ass = 0.02; Table 2). 
 
Considering the low number of homozygotes found in DS, a RS was used and 767 DTC cases and 2429 
controls were genotyped (Table 3). The A-allele of rs2480258 was associated in a statistically significant 
way with the risk (OR = 1.17, 95 % CI = 1.02–1.33; P ass = 0.02). Under the hypothesis of the additive 
model (P trend = 0.023), heterozygotes and homozygotes showed a trend of increased risk (OR = 1.24, 95 % 
CI = 1.03–1.48, P ass = 0.02 and OR = 1.56, 95 % CI = 1.06–2.30, P ass = 0.02, respectively). When the groups 
of DS and RS were pooled (1117 DCT and 2779 controls) the results were confirmed, reinforcing the 
statistical power of the study. The per-allele risk (A-allele vs. G-allele) was OR = 1.17 (95 % CI = 1.04–
1.31; Pass = 0.008), and heterozygotes and homozygotes showed an OR = 1.20 (95 % CI = 1.02–
1.40; Pass = 0.02) and OR = 1.68 (95 % CI = 1.20–2.35; P ass = 0.002), respectively. The per-allele and rare 
homozygotes statistical significance held also following corrections for multiple testing (q-values of 0.04 
and 0.01, respectively). 
Functional assessment of CYP2E1 polymorphisms in human liver 
Following these positive results, we performed a genotype–phenotype correlation analysis in 149 human 
liver samples with phenotypic data for the mRNA expression, protein levels, and enzymatic activity of 
microsomal CYP2E1. We found that rs2515642, a SNP with available genotype information assessed by 
microarray (Schröder et al. 2013) and in strong LD with rs2480258 (r 2 = 0.96), was significantly 
associated with a reduced CYP2E1 expression phenotype, at the level of mRNA, protein, and enzymatic 
activity (Fig. 1; upper panel). When rs2480258 genotypes were imputed, we observed similar genotype 
frequencies (GG: 68 %; GA: 29 %; AA: 3 %) in human liver subjects compared to the frequencies in the DS 
and RS cohorts. The association was confirmed, in that compared to the homozygous G-allele, the A-
allele was significantly associated with lower levels of mRNA (GA: 0.83-fold, P = 0.04; AA: 0.33-
fold, P = 0.002), protein (GA: 0.74-fold, P = not significant; AA: 0.47-fold, P = 0.03), and chlorzoxazone 6-
hydroxylation (GA: 0.79-fold, P = 0.02; AA: 0.8-fold, P = not significant; Fig. 1; lower panel). Multivariate 
analysis using the same three genetic models and correction for covariates (sex, age, nicotine and alcohol 
consumption, presurgical drug exposure, C-reactive protein, cholestasis, and diagnosis leading to liver 
resection) confirmed the significant associations of the A-allele with lower mRNA (additive 
model; P = 0.01), lower protein levels (additive model; P = 0.01), and decreased enzyme activity (additive 
model; P = 0.04). 
 
As shown in Table 4, only two main haplotypes, #1 and #2, are prevalent among Caucasians in the third 
LD block, marked by the low-expression allele rs2480258, with frequencies of 0.759 and 0.234, 
respectively. Within this block the SNPs rs2515642, rs2480259, rs2480258, rs2249694, and rs2249695 
were evaluated for altering the splicing efficiency of the intron VIII. However, no differences were noted 
(data not reported for brevity). The SNPs located within the 3′UTR (rs24080257 and rs2480256) were 
evaluated as putative miRSNPs (i.e., polymorphisms located within miRNA-binding target sites), and the 
A-allele of rs2480257 was predicted to affect a conserved binding site for hsa-miR-5582-3p, hsa-miR-570-
3p, and hsa-miR-203a. On the other hand, the A-allele of rs2480256 was predicted to affect two miRNA 
binding sites: one for hsa-miR-510-3p and another for hsa-miR-570-3p (results presented in 
supplementary Table 1). Thus, hsa-miR-570-3p was predicted to be affected by both polymorphisms. 
 
Discussion 
Over a hundred case–control association studies were published on SNPs within CYP2E1 in relation to the 
risk of various diseases. As showed in Fig. 2 (and supplementary Table 2), most of them focused on the 
alleles *5A, *5B, or *6 (i.e., rs2031920, RsaI, and rs3813867, PstI, at the 5′ region, or rs6413432, DraI, 
within intron VI, respectively). 
To our knowledge, this is the first study to evaluate multiple regions of the CYP2E1 locus in relation to 
the risk of DTC. 
A novel association for rs2480258, a ht-SNP within a LD block spanning intron VIII and the 3′ UTR of the 
gene, was found, in that the minor allele was associated with increased risk for DTC (Table  3). 
Interestingly, we found that the minor allele of rs2480258 was also associated with a reduced CYP2E1 
expression phenotype at three levels, i.e., mRNA, protein, and CYP2E1 enzyme activity, in a panel of 149 
liver tissues. In order to better understand the biology of CYP2E1, all the intron VIII and 3′UTR SNPs of 
the LD block marked by rs2480258 were evaluated in silicofor predicting their biological effects. While no 
consequences were noted for the splicing of intron VIII, the two haplotypes showed differences in regard 
to the binding of four microRNAs (miRNAs): hsa-miR-5582-3p, hsa-miR-570-3p, hsa-miR-203a, and hsa-
miR-510-3p. It could thus be speculated that carriers of haplotype #2 have an altered miRNA-
dependent CYP2E1regulation, leading to reduced CYP2E1 protein levels and activity (i.e., a “slow 
metabolizer” phenotype). Although limited information is available for the predicted miRNAs hsa-miR-
203a, which was found down-regulated in central nervous system (Gaur et al. 2007) and up-regulated in 
breast (Iorio et al. 2005), and colorectal cancer (Bandrés et al. 2006), varied expression was observed for 
hsa-miR-570-3p in hepatoma-Hepg2, osteosarcoma-U20 s, lung adenocarcinoma A549-I, renal 
carcinoma-DH, neuroblastoma SHSYSY, and Burkitt-DG-75 cancer cell lines (http://www.microrna.org). 
No robust information is available for thyroid carcinoma. Of interest and in agreement with our in 
silico prediction, miR-570 was recently shown to be expressed in healthy human liver and to negatively 
regulate CYP2E1 protein expression by translational repression in cell culture and tissue depending on 
the genotype for the 3′UTR SNPs rs2480256 and rs2480257 (which are linked to the DTC risk allele 
rs2480258, see above) (Nakano et al. 2015).We acknowledge that our results seem to be counterintuitive 
with respect to the starting hypothesis. Thus, metabolic activation of AA to GA by CYP2E1 should be 
reduced in individuals with slow metabolizer phenotype, e.g., carriers of haplotype #2, resulting in 
decreased cancer risk, if GA is considered to be the ultimate carcinogen. As the present findings are in 
contrast to this expectation, they may point at a more differentiated role of dietary AA in the 
development of DTC. In slow metabolizers, circulating levels of AA should be elevated for prolonged 
times, so that target organs such as the thyroid may be reached more easily, where conversion into GA 
may take place in organo. However, available data do not support substantial expression of CYP2E1 in 
the thyroid. Alternatively, AA itself could exert its toxic effects directly. For example, AA was found to be 
clastogenic and toxic for neurological and reproductive systems (Besaratinia and Pfeifer 2003; Koyama et 
al. 2006). AA may also act indirectly as an endocrine disruptor, as it was found to be associated with 
various sex hormone levels (Hogervorst et al. 2013). The finding that tissue and organ distribution of GA-
DNA adducts does not correlate with AA-induced tumors in rat organs and reinforces the role of a direct 
effect of AA (Segerbäck et al. 1995). 
Of course we also acknowledge that there are some limitations. For example, information collected for 
diet and smoking habits was limited and cases and controls were not frequency-matched for gender or 
age, although these covariates were taken into account by the statistical model allowing the adjustment 
of ORs. However, we believe that the association described in this study is not a chance finding. In fact, 
the study had an adequate statistical power to detect small effect sizes, given the large sample size of 
cases and controls genotyped. In addition, the results were replicated in two independent sample sets 
(DS and RS). 
Furthermore, the significance of CYP2E1 mRNA for functional phenotype remains mysterious. While miR-
570 offers a mechanistic explanation for the lower expression of the rs2480258-tagged DTC risk allele on 
the protein level, there exist inconsistent data regarding the mRNA level. The study of Nakano et al. 
(2015) as well as preliminary results from additional eQTL datasets seems not to replicate the effect of 
the A-allele of rs2480258 on mRNA expression (Eric Schadt, personal communication; ES and FI, 
unpublished data). Such differences could be ascribed to the different origins of the liver samples, i.e., 
normal hepatic tissues withdrawn from patients undergone surgical resection for hepatocellular 
carcinoma (Schröder et al. 2013) or normal livers from postmortem resections (Seiser et al. 2014; Schadt 
et al. 2008). Further functional assessment of these liver tissues by comparable methods and assays 
should therefore be performed on this allele in future studies. 
In conclusion, we are aware that present results do not provide direct proofs on a problematic role of AA 
for human health. The departing hypothesis suggested CYP2E1 as a promising candidate gene to be 
evaluated, but our positive findings could be explained also by the biotransformation of other xenobiotic 
or endogenous molecules, in a more complex gene–environment interaction. In any case, the role of 
CYP2E1 for thyroid carcinogenesis is suggested here. Considering the large amount of previous positive 
studies (Fig. 2), CYP2E1 appears as a key xenobiotic metabolizing enzyme involved in the genetic 
susceptibility of several types of cancer and the biotransformation of AA may play a role for most of 
them. In the future, in vivo studies investigating AA metabolism in relation to CYP2E1 haplotype #2 
should be undertaken, in order to provide more direct evidences on the role of CYP2E1 and AA in human 
health. 
Acknowledgements 
This work was funded by a grant from Istituto Toscano Tumori (Florence, Italy), the Robert Bosch 
Foundation, Stuttgart, Germany (to U.M.Z), and by NIH/NIDDK R21DK081157-01A2 and NIH/NCI 
K07CA140390-01. The authors thank Uwe Fuhr and Roberto Barale for helpful suggestions. 
Conflict of interest. The authors declare that they have no conflict of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 References 
1. Andrés E, Cubedo E, Agirre X et al (2006) Identification by Real-time PCR of 13 mature microRNAs 
differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5:29. doi: 10.1186/1476-
4598-5-29 
2. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics 21:263–265. doi: 10.1093/bioinformatics/bth457 
3. Beland FA, Mellick PW, Olson GR et al (2013) Carcinogenicity of acrylamide in B6C3F(1) mice and 
F344/N rats from a 2-year drinking water exposure. Food Chem Toxicol 51:149–159. doi: 
10.1016/j.fct.2012.09.017 
4. Benjamini Y, Drai D, Elmer G et al (2001) Controlling the false discovery rate in behavior genetics 
research. Behav Brain Res 125:279–284. doi: 10.1016/S0166-4328(01)00297-2 
5. Besaratinia A, Pfeifer GP (2003) Weak yet distinct mutagenicity of acrylamide in mammalian cells. J 
Natl Cancer Inst 95:889–896 
6. Bhattacharya A, Ziebarth JD, Cui Y (2014) PolymiRTS Database 3.0: linking polymorphisms in 
microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res 42:D86–
D91. doi: 10.1093/nar/gkt1028 
7. Cancemi L, Romei C, Bertocchi S et al (2011) Evidences that the polymorphism Pro-282-Ala within 
the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. Int J Cancer 
129:2816–2824. doi: 10.1002/ijc.25937 
8. Cardis E, Kesminiene A, Ivanov V et al (2005) Risk of thyroid cancer after exposure to 131I in 
childhood. J Natl Cancer Inst 97:724–732. doi: 10.1093/jnci/dji129 
9. Colonna M, Bossard N, Guizard A-V et al (2010) Descriptive epidemiology of thyroid cancer in 
France: incidence, mortality and survival. Ann Endocrinol 71:95–101. doi: 10.1016/j.ando.2009.11.006 
(Paris) 
10. Delaneau O, Marchini J, Zagury J-F (2012) A linear complexity phasing method for thousands of 
genomes. Nat Methods 9:179–181. doi: 10.1038/nmeth.1785 
11. Doroshyenko O, Fuhr U, Kunz D et al (2009) In vivo role of cytochrome P450 2E1 and glutathione-S-
transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiol Biomarkers Prev 18:433–
443. doi: 10.1158/1055-9965.EPI-08-0832 
12. EFSA (European Food Safety Authority) (2011) Results on acrylamide levels in food from monitoring 
years 2007–2009 and exposure assessment. http://www.efsa.europa.eu/it/efsajournal/doc/2133.pdf 
13. EFSA (European Food Safety Authority) (2012) Update on acrylamide levels in food from monitoring 
years 2007 to 2010. http://www.efsa.europa.eu/en/efsajournal/doc/2938.pdf 
14. Fioretti F, Tavani A, Gallus S, Franceschi S, Negri E, La Vecchia C (1999) Case-control study of thyroid 
cancer in Northern Italy: attributable risk. Int J Epidemiol 28:626–630 
15. Freidlin B, Zheng G, Li Z, Gastwirth JL (2002) Trend tests for case-control studies of genetic markers: 
power, sample size and robustness. Hum Hered 53:146–152 
16. Freisling H, Moskal A, Ferrari P et al (2013) Dietary acrylamide intake of adults in the European 
Prospective Investigation into Cancer and Nutrition differs greatly according to geographical region. Eur J 
Nutr 52:1369–1380. doi: 10.1007/s00394-012-0446-x 
17. Friedman M (2003) Chemistry, biochemistry, and safety of acrylamide. A review. J Agric Food Chem 
51:4504–4526. doi: 10.1021/jf030204+ 
18. Friedman MA, Dulak LH, Stedham MA (1995) A lifetime oncogenicity study in rats with acrylamide. 
Fundam Appl Toxicol 27:95–105 
19. Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human 
genome. Science 296:2225–2229. doi: 10.1126/science.1069424 
20. Gaur A, Jewell DA, Liang Y et al (2007) Characterization of microRNA expression levels and their 
biological correlates in human cancer cell lines. Cancer Res 67:2456–2468. doi: 10.1158/0008-5472.CAN-06-
2698 
21. Ghanayem BI, McDaniel LP, Churchwell MI et al (2005) Role of CYP2E1 in the epoxidation of 
acrylamide to glycidamide and formation of DNA and hemoglobin adducts. Toxicol Sci 88:311–318. doi: 
10.1093/toxsci/kfi307 
22. Gomes AM, Winter S, Klein K et al (2009) Pharmacogenomics of human liver cytochrome P450 
oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 
10:579–599. doi: 10.2217/pgs.09.7 
23. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X, Moreno V (2007) SNPassoc: an R 
package to perform whole genome association studies. Bioinformatics 23:644–645 
24. Grande E, Díez JJ, Zafon C, Capdevila J (2012) Thyroid cancer: molecular aspects and new 
therapeutic strategies. J Thyroid Res. doi: 10.1155/2012/847108Central 
25. Hogervorst JG, Schouten LJ, Konings EJ et al (2007) A prospective study of dietary acrylamide intake 
and the risk of endometrial, ovarian, and breast cancer. Cancer Epidemiol Biomarkers Prev 16:2304–2313. 
doi: 10.1158/1055-9965.EPI-07-0581 
26. Hogervorst JG, Fortner RT, Mucci LA et al (2013) Associations between dietary acrylamide intake 
and plasma sex hormone levels. Cancer Epidemiol Biomarkers Prev 22:2024–2036. doi: 10.1158/1055-
9965.EPI-13-0509 
27. Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype imputation method for 
the next generation of genome-wide association studies. PLoS Genet 5:e1000529. doi: 
10.1371/journal.pgen.1000529Central 
28. Huang Y-F, Chiang S-Y, Liou S-H et al (2012) The modifying effect of CYP2E1, GST, and mEH 
genotypes on the formation of hemoglobin adducts of acrylamide and glycidamide in workers exposed to 
acrylamide. Toxicol Lett 215:92–99. doi: 10.1016/j.toxlet.2012.10.003 
29. Iarc 1994 (1994) Monographs on the evaluation of carcinogenic risks to humans 
http://monographs.iarc.fr/ENG/Monographs/vol60/mono60.pdf 
30. Iorio MV, Ferracin M, Liu C-G et al (2005) MicroRNA gene expression deregulation in human breast 
cancer. Cancer Res 65:7065–7070. doi: 10.1158/0008-5472.CAN-05-1783 
31. Johnson KA, Gorzinski SJ, Bodner KM et al (1986) Chronic toxicity and oncogenicity study on 
acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol 85:154–168 
32. Khan MA, Davis CA, Foley GL et al (1999) Changes in thyroid gland morphology after acute 
acrylamide exposure. Toxicol Sci 47:151–157 
33. Klein K, Winter S, Turpeinen M et al (2010) Pathway-targeted pharmacogenomics of CYP1A2 in 
human liver. Front Pharmacol. doi: 10.3389/fphar.2010.00129Central 
34. Koyama N, Sakamoto H, Sakuraba M et al (2006) Genotoxicity of acrylamide and glycidamide in 
human lymphoblastoid TK6 cells. Mutat Res 603:151–158. doi: 10.1016/j.mrgentox.2005.11.006 
35. Malchoff CD, Malchoff DM (2004) Familial papillary thyroid carcinoma. Cancer Treat Res 122:381–
387 
36. Maronpot RR, Thoolen RJMM, Hansen B (2015) Two-year carcinogenicity study of acrylamide in 
Wistar Han rats with in utero exposure. Exp Toxicol Pathol 67:189–195. doi: 10.1016/j.etp.2014.11.009 
37. Mei N, Guo L, Tseng J et al (2008) Gene expression changes associated with xenobiotic metabolism 
pathways in mice exposed to acrylamide. Environ Mol Mutagen 49:741–745. doi: 10.1002/em.20429 
38. Mottram DS, Wedzicha BL, Dodson AT (2002) Acrylamide is formed in the Maillard reaction. Nature 
419:448–449. doi: 10.1038/419448a 
39. Naccarati A, Pardini B, Stefano L et al (2012) Polymorphisms in miRNA-binding sites of nucleotide 
excision repair genes and colorectal cancer risk. Carcinogenesis 33:1346–1351. doi: 10.1093/carcin/bgs172 
40. Nakano M, Mohri T, Fukami T et al (2015) Single-nucleotide polymorphisms in cytochrome P450 
2E1 (CYP2E1) 3’-untranslated region affect the regulation of CYP2E1 by miR-570. Drug Metab Dispos 
43:1450–1457. doi: 10.1124/dmd.115.065664 
41. Neafsey P, Ginsberg G, Hattis D et al (2009) Genetic polymorphism in CYP2E1: Population 
distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 12:362–388. doi: 
10.1080/10937400903158359 
42. Obón-Santacana M, Kaaks R, Slimani N et al (2014) Dietary intake of acrylamide and endometrial 
cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Br J Cancer 
111:987–997. doi: 10.1038/bjc.2014.328Central 
43. Pedreschi F, Mariotti MS, Granby K (2014) Current issues in dietary acrylamide: formation, 
mitigation and risk assessment. J Sci Food Agric 94:9–20. doi: 10.1002/jsfa.6349 
44. Pelucchi C, La Vecchia C, Bosetti C et al (2011) Exposure to acrylamide and human cancer—a review 
and meta-analysis of epidemiologic studies. Ann Oncol 22:1487–1499. doi: 10.1093/annonc/mdq610 
45. Piva F, Giulietti M, Nocchi L, Principato G (2009) SpliceAid: a database of experimental RNA target 
motifs bound by splicing proteins in humans. Bioinformatics 25:1211–1213. doi: 
10.1093/bioinformatics/btp124 
46. R Core Team (2014) R: a language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org/ 
47. Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J 
Comput Biol 4:311–323 
48. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of 
microRNA/target duplexes. RNA 10:1507–1517. doi: 10.1261/rna.5248604Central 
49. Rieger JK, Klein K, Winter S, Zanger UM (2013) Expression variability of absorption, distribution, 
metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association 
with gene expression. Drug Metab Dispos 41:1752–1762. doi: 10.1124/dmd.113.052126 
50. Ron E (2007) Thyroid cancer incidence among people living in areas contaminated by radiation from 
the chernobyl accident. Health Phys 93:502–511. doi: 10.1097/01.HP.0000279018.93081.29 
51. Schadt EE, Molony C, Chudin E et al (2008) Mapping the genetic architecture of gene expression in 
human liver. PLoS Biol 6:e107. doi: 10.1371/journal.pbio.0060107Central 
52. Schröder A, Klein K, Winter S et al (2013) Genomics of ADME gene expression: mapping expression 
quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human 
liver. Pharmacogenomics J 13:12–20. doi: 10.1038/tpj.2011.44 
53. Segerbäck D, Calleman CJ, Schroeder JL et al (1995) Formation of N-7-(2-carbamoyl-2-
hydroxyethyl)guanine in DNA of the mouse and the rat following intraperitoneal administration of 
[14C]acrylamide. Carcinogenesis 16:1161–1165 
54. Seiser EL et al (2014) Meta-analysis of liver eQTL studies and cross-tissue eQTL comparison using 
GTEx Data. http://www.ashg.org/2014meeting/abstracts/fulltext/f140123474.htm. 
http://www.ashg.org/2014meeting/abstracts/fulltext/f140123474.htm. Accessed 24 Jul 2015 
55. Settels E, Bernauer U, Palavinskas R et al (2008) Human CYP2E1 mediates the formation of 
glycidamide from acrylamide. Arch Toxicol 82:717–727. doi: 10.1007/s00204-008-0296-8 
56. Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol 
22:395–404. doi: 10.1016/j.clon.2010.05.004 
57. Stadler RH, Blank I, Varga N et al (2002) Acrylamide from Maillard reaction products. Nature 
419:449–450. doi: 10.1038/419449a 
58. Sumner SC, Fennell TR, Moore TA et al (1999) Role of cytochrome P450 2E1 in the metabolism of 
acrylamide and acrylonitrile in mice. Chem Res Toxicol 12:1110–1116 
59. Surks MI, Chopra IJ, Mariash CN et al (1990) American Thyroid Association guidelines for use of 
laboratory tests in thyroid disorders. JAMA 263:1529–1532 
60. Tareke E, Rydberg P, Karlsson P et al (2002) Analysis of acrylamide, a carcinogen formed in heated 
foodstuffs. J Agric Food Chem 50:4998–5006 
61. Tremmel R, Klein K, Winter S, Schaeffeler E, Zanger UM (2015) Gene copy number variation analysis 
reveals dosage-insensitive expression of CYP2E1. Pharmacogenomics J. doi: 10.1038/tpj.2015.69 
62. Yaylayan VA, Machiels D, Istasse L (2003) Thermal decomposition of specifically phosphorylated D-
glucoses and their role in the control of the Maillard reaction. J Agric Food Chem 51:3358–3366. doi: 
10.1021/jf034037p 
63. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene 
expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141. doi: 
10.1016/j.pharmthera.2012.12.007 
64. Ziebarth JD, Bhattacharya A, Chen A, Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in 
microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216–D221. doi: 
10.1093/nar/gkr1026 
65. Zyzak DV, Sanders RA, Stojanovic M et al (2003) Acrylamide formation mechanism in heated foods. 
J Agric Food Chem 51:4782–4787. doi: 10.1021/jf034180i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Characteristics of controls and DTC patients 
  Discovery set Replication set 
  Controls N
(%) 
Cases N(%
) 
OR
a
(95 
% CI) 
P value Controls N
(%) 
Cases N (
%) 
OR 
(95 % 
CI) 
P value 
Sex 
 Male 195 
(56.0 %) 
97 
(27.7 %) 
Refere
nce 
  1441 
(51.8 %) 
296 
(26.5 %) 
Refere
nce 
  
 Female 155 
(44.0 %) 
253 
(72.3 %) 
3.28 
(2.39–
4.50) 
<10−6a 1338 
(48.2 %) 
821 
(73.5 %) 
2.97 
(2.55–
3.46) 
<10−6a 
Age (years) 
 Average 49.26 ± 6.
82 
45.62 ± 13
.72 
  8.7 × 1
0−5b 
49.30 ± 14
.13 
45.85 ± 13
.06 
  <10−6b 
 Median 48.0 45.0     48.0 45.0     
Body mass index 
 Average 25.54 ± 3.
29 
26.17 ± 4.
93 
  0.047b 25.70 ± 4.
28 
25.90 ± 4.
73 
  0.08b 
 Median 25.26 25.57     25.00 25.20     
Smoking 
 Non-
smokers 
240 
(68.6 %) 
212 
(60.6 %) 
Refere
nce 
  1844 
(66.4 %) 
660 
(59.2 %) 
Refere
nce 
  
 Smokers +
 Ex-
smokers 
110 
(31.4 %) 
138 
(39.4 %) 
1.42 
(1.04–
1.94) 
0.027a 935 
(33.6 %) 
457 
(40.8 %) 
1.37 
(1.18–
1.57) 
1.71 × 1
0−5a 
 Total 350 350     2779 1117     
Diagnosis 
 PTCc   322 
(92.0 %) 
      1030 
(92.2 %) 
    
 FTCd   28 (8.0 %)       87 (7.8 %)     
Smoker quitters were grouped with smokers, and volunteers exposed to passive cigarette smoke are 
grouped with non-smokers  
aCrude odds ratio from logistic regression analysis 
b P values from t Student’s test 
cPapillary 
dFollicular thyroid carcinoma 
 
  
Table 2 
Statistical analyses for SNPs within CYP2E1 gene on discovery set 
  Controls N (%) DTC N (%) Orb (95 % CI) P value 
rs9418982 
 C-allelea 154 (22.1 %) 149 (21.2 %) 0.95 (0.74–1.22) 0.67c 
Genotypes 
 T/T 213 (60.8 %) 217 (62.2 %) Reference   
 T/C 120 (34.2 %) 117 (33.3 %) 1.00 (0.69–1.45) 1.00d 
 C/C 17 (5.0 %) 16 (4.5 %) 0.80 (0.35–1.83) 0.60d 
 Best modele Additive; P-trend = 0.675 
rs7092584 
 T-allelea 67 (18.7 %) 67 (19.3 %) 1.04 (0.72–1.49) 0.84c 
Genotypes 
 C/C 288 (82.2 %) 285 (81.3 %) Reference   
 C/T 59 (16.9 %) 63 (18.1 %) 1.37 (0.85–2.21) 0.20d 
 T/T 3 (0.9 %) 2 (0.6 %) 0.69 (0.06–7.41) 0.76d 
 Best modele Additive; P-trend = 0.656 
rs743534 
 G-allelea 114 (16.2 %) 73 (16.2 %) 0.95 (0.70–1.30) 0.71c 
Genotypes 
 T/T 241 (69.0 %) 276 (78.9 %) Reference   
 T/G 104 (29.6 %) 67 (19.2 %) 1.00 (0.67–1.50) 1.00d 
  Controls N (%) DTC N (%) Orb (95 % CI) P value 
 G/G 5 (1.4 %) 7 (1.9 %) 0.83 (0.18–3.70) 0.81d 
 Best modele Dominant; P-trend = 0.369 
rs2480258 
 A-allelea 151 (21.6 %) 173 (24.7 %) 1.19 (0.93–1.53) 0.16c 
Genotypes 
 G/G 209 (59.7 %) 200 (57.1 %) Reference   
 G/A 131 (37.4 %) 127 (36.3 %) 1.06 (0.76–1.48) 0.70d 
 A/A 10 (2.9 %) 23 (6.6 %) 2.63 (1.15–6.03) 0.02 d 
 Best modele Recessive; P-trend = 0.020 
 A/A vs. (G/G + G/A) 340 (97.1 %) 327 (93.4 %) 2.57 (1.14–5.83) 0.02 d 
Significant P values are in bold 
aMinor allele frequency 
bAdjusted by age, gender, BMI, and smoke 
cTwo-sided Chi-square test for distribution of allelic frequencies 
dP-association of the odds ratio from multivariate logistic regression analysis adjusted for covariates 
eBest model for NMTC (Non-medullary thyroid carcinomas), according to the Cochran–Armitage trend test 
Analyses in the replication set 
 
  
Table 3 
Statistical analyses for rs2480258 on replication set and all sample set 
  Replication set Pooled sets 
Controls N(
%) 
DTC N (%) OR
b
 (95 
% CI) 
Pvalu
e 
Controls N (
%) 
DTC N(%
) 
OR
b
 (95 
% CI) 
Pvalu
e 
rs2480258 
 A-
allelea 
1078 
(22.2 %) 
383 (25.0 %) 1.17 
(1.02–
1.33) 
0.02c 1229 
(22.1 %) 
556 
(24.9 %) 
1.17 
(1.04–
1.31) 
0.008c 
Genotypes 
 G/G 1461 
(60.2 %) 
431 (56.2 %) Referenc
e 
  1670 
(60.1 %) 
631 
(56.9 %) 
Referenc
e 
  
 G/A 858 (35.3 %) 289 (37.7 %) 1.24 
(1.03–
1.48) 
0.02d 989 (35.6 %) 416 
(36.9 %) 
1.20 
(1.02–
1.40) 
0.02 d 
 A/A 110 (4.5 %) 47 (6.1 %) 1.56 
(1.06–
2.30) 
0.02d 120 (4.3 %) 70 
(6.2 %) 
1.68 
(1.20–
2.35) 
0.002
d 
Best 
model
e 
Additive; P-
trend = 0.02
3 
Additive; P-
trend = 0.00
8 
            
Total 2429 767     2779 1117     
Significant P values are in bold 
aMinor allele frequency 
bAdjusted by age, gender, BMI, and smoke 
cTwo-sided Chi-square test for distribution of allelic frequencies 
dP-association of the odd ratio from multivariate logistic regression analysis adjusted for covariates 
ebest model for NMTC, according to the Cochran–Armitage trend test 
 
 
 
 
 
 
  
 Fig. 1 
CYP2E1 genotype–phenotype correlation analysis in 149 human liver subjects. Relative CYP2E1 mRNA 
expression, measured using qPCR, protein levels, determined by Western blot analysis, and enzyme 
activity, quantified by LC-MSMS analysis of chlorzoxazone-6-hydroxylation (mg indicates mg of 
microsomal protein), are plotted against the genotypes of a rs2515642 and b rs2480258 as box-and-
whisker plots with outliers. Statistically significant P values <0.05 are displayed (pairwise t tests) 
 
 
 
 
 
 
 
 
 
  
Table 4 
SNPs within the 3′UTR of CYP2E1 gene are in high linkage disequilibrium with various other SNPs in the 
nearby region leading to only two prevalent haplotypes (1 and 2) surrounding the 3′UTR, in the Caucasian 
population (data from www.1000Genomes.org) 
SNP ID Chromosome 
10 
Gene 
region 
Haplotype 
#1 #2 #3 #4 #5 #6 
rs2515642 133,538,509 IVS8 T C T T T T 
rs2480259 133,538,572 IVS8 G A G G G G 
rs2480258
a
 133,538,596 IVS8 C T C T C C 
rs2249694 133,538,649 IVS8 G A G G A G 
rs2249695 133,538,664 IVS8 C T C C C C 
rs2480257 133,539,005 3′UTR A T T A A A 
rs2480256 133,539,010 3′UTR G A A G G G 
rs2480255 133,539,351 3′flank C T C C C T 
rs2480254 133,539,365 3′flank C T C C C T 
rs2515644 133,539,575 3′flank C A C C C C 
    Frequency 0.759 0.234 0.004 0.001 0.001 0.001 
All SNPs are mapped to the forward strand on the reference assembly (GRCh38) 
aht-SNP 
 
 
 
 
 
 
 
  
  
Fig. 2 
Graph representing published case–control association studies on specific polymorphisms of CYP2E1 in 
relation with the risk of various types of diseases (not limited to cancer) in humans. Black dots represent 
significant associations at 0.05 level, gray dots represent associations with P values ranging between 0.05 
and 0.10, white dots represent negative studies. The structure of the gene is over-imposed on the top of 
the LD structure. The LD measure is the r 2 (black, LD = 1; white, LD = 0). See supplementary Table 2 for 
further details on studies 
 
 
 
 
 
 
 
 
 
